Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report)'s share price fell 4.1% on Friday . The stock traded as low as $76.39 and last traded at $76.73. 62,106 shares were traded during mid-day trading, a decline of 1% from the average session volume of 62,645 shares. The stock had previously closed at $80.01.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the company. William Blair initiated coverage on Korro Bio in a research note on Wednesday, August 14th. They set an "outperform" rating and a $180.00 price objective for the company. HC Wainwright upped their price target on shares of Korro Bio from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Royal Bank of Canada restated an "outperform" rating and set a $95.00 price objective on shares of Korro Bio in a research note on Thursday, September 19th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $138.00.
Get Our Latest Research Report on KRRO
Korro Bio Trading Up 0.0 %
The business has a fifty day moving average price of $41.33 and a 200-day moving average price of $47.86.
Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.39) by ($0.04). On average, analysts predict that Korro Bio, Inc. will post -10.09 EPS for the current year.
Insider Activity at Korro Bio
In other Korro Bio news, CFO Vineet Agarwal sold 10,216 shares of the company's stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $78.26, for a total value of $799,504.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 16.80% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of KRRO. Brown Brothers Harriman & Co. bought a new stake in Korro Bio during the second quarter valued at about $28,000. Lynx1 Capital Management LP purchased a new position in Korro Bio in the 2nd quarter worth approximately $129,000. Rhumbline Advisers purchased a new position in Korro Bio in the 2nd quarter worth approximately $279,000. Bank of New York Mellon Corp bought a new position in Korro Bio in the 2nd quarter worth approximately $649,000. Finally, Tri Locum Partners LP bought a new position in Korro Bio in the 2nd quarter worth approximately $2,419,000. Institutional investors own 13.18% of the company's stock.
Korro Bio Company Profile
(
Get Free Report)
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Recommended Stories
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
